1-carbamoyloxy-piperidine | 99115-43-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-carbamoyloxy-piperidine
• 英文别名: 1-Carbamoyloxy-piperidin；Piperidin-1-yl carbamate
• CAS: 99115-43-2
• 化学式: C₆H₁₂N₂O₂
• mdl: MFCD19208113
• 分子量: 144.173
• InChiKey: YIEQOVNJPCLEAV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-羟基哌啶 在 盐酸 、 potassium cyanate 、 水 作用下， 生成 1-carbamoyloxy-piperidine
  参考文献：
  名称：

  [异羟基脲及其烷基和亚烷基衍生物]。

  摘要：

  DOI：

  10.1002/ardp.19592920102

文献信息

• TREPROSTINIL PRODRUGS
  申请人：United Therapeutics Corporation

  公开号：US20210054009A1

  公开（公告）日：2021-02-25

  Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.

  提供了特瑞普罗斯汀的新型前药，以及制备这些前药的方法和使用这些前药的方法。
• [EN] SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE<br/>[FR] CARBAMATES DE PIPERIDINE A SUBSTITUTION UTILISES EN TANT QU'INHIBITEURS DE LA LIPASE HORMONOSENSIBLE
  申请人：NOVO NORDISK AS

  公开号：WO2004111032A1

  公开（公告）日：2004-12-23

  Novel substituted piperidine carbamates, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to hormone sensitive lipase. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which modulation of the activity of hormone sensitive lipase is beneficial.

  新型替代哌啶羰酸酯化合物，包括它们的药物组合物以及在治疗和/或预防与激素敏感性脂肪酶相关的疾病和紊乱中的应用。更具体地说，这些化合物对于治疗和/或预防需要调节激素敏感性脂肪酶活性的疾病和紊乱是有益的。
• NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT
  申请人：Shionogi & Co., Ltd.

  公开号：US20190161501A1

  公开（公告）日：2019-05-30

  Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): wherein ring A is a heterocycle, X 1 is each independently CR 4a R 4b , X 2 is each independently CR 4c R 4d , Y 1 and Y 2 are each independently a carbon atom or a nitrogen atom, L is —N(R 6 )—C(═O)— or the like, W is cyclyl or the like, R 2 and R 3 are each independently substituted or unsubstituted alkyl or the like, R 1a , R 1b , R 4a to R 4d , and R 6 are each independently hydrogen atoms or the like, p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.

  提供具有D3受体拮抗活性的新化合物。一种由以下式（I）表示的化合物：其中环A是杂环，X1分别是CR4aR4b，X2分别是CR4cR4d，Y1和Y2分别是碳原子或氮原子，L是—N(R6)—C(═O)—或类似物，W是环烷基或类似物，R2和R3分别是取代或未取代的烷基或类似物，R1a、R1b、R4a到R4d和R6分别是氢原子或类似物，p为1或2，q是1到3的整数，n是1到4的整数，s是0到4的整数，或其药学上可接受的盐。
• CHEMICALLY ACTIVATED WATER-SOLUBLE PRODRUG
  申请人：SUMITOMO DAINIPPON PHARMA CO., LTD

  公开号：US20200207782A1

  公开（公告）日：2020-07-02

  The present invention addresses the problem of providing a novel chemically activated water-soluble prodrug. The present invention provides a compound represented by formula (1), or a pharmacologically acceptable salt thereof (in the formula, A represents A-0; X 1 and X 2 are the same as or different from each other and each independently represent a hydroxyl group or —O—C(═O)—Y—(C(R 1A ) (R 1B ))n-NH—R 2 , where X 1 and X 2 are not simultaneously hydroxyl groups, n is 2, 3, or 4, Y represents an oxygen atom or —NR 4 , R 1A and R 1B are the same as or different from each other and each independently represent a hydrogen atom, etc., and R 2 represents a hydrogen atom, etc.; and R a to R d are optionally present, are the same as or different from each other, and each independently represent a hydrogen atom, etc.).

  本发明解决了提供一种新型化学活化的水溶性前药的问题。本发明提供了由式（1）表示的化合物，或其药理学上可接受的盐（在该式中，A代表A-0；X1和X2彼此相同或不同，每个独立地代表一个羟基或—O—C(═O)—Y—(C(R1A)(R1B))n-NH—R2，其中X1和X2不同时是羟基，n为2、3或4，Y代表氧原子或—NR4，R1A和R1B彼此相同或不同，每个独立地代表氢原子等，R2代表氢原子等；以及Ra到Rd可选地存在，彼此相同或不同，每个独立地代表氢原子等）。
• [EN] COMPOUNDS AND METHODS FOR TREATING CANCER, VIRAL INFECTIONS, AND ALLERGIC CONDITIONS<br/>[FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT DU CANCER, D'INFECTIONS VIRALES ET D'AFFECTIONS ALLERGIQUES
  申请人：JANETKA JAMES

  公开号：WO2020264187A1

  公开（公告）日：2020-12-30

  The present invention generally relates to compounds that are useful for inhibiting one or more trypsin-like S1 serine proteases, HGFA, matriptase, hepsin, KLK5 and/or TMPRSS2 as well as cysteine proteases including trypsin-like cysteine proteases (e.g. Cathepsin B). The present invention also relates to various methods of using the inhibitor compounds to treat or prevent viral infections, including those caused by coronaviruses and influenza, conditions associated with KLK5, various malignancies, pre-malignant conditions, and cancer.

  本发明通常涉及一种用于抑制一个或多个类似胰蛋白酶的S1丝氨酸蛋白酶，HGFA、matriptase、hepsin、KLK5和/或TMPRSS2以及胱氨酸蛋白酶包括类似胰蛋白酶的胱氨酸蛋白酶（例如Cathepsin B）的化合物。本发明还涉及使用这些抑制剂化合物治疗或预防病毒感染的各种方法，包括由冠状病毒和流感病毒引起的感染，与KLK5相关的疾病、各种恶性肿瘤、癌前病变和癌症。